Ketamine therapy is one of the most curiosity-driven, jargon-heavy specialties in healthcare. Patients arrive after reading a New York Times article, a Reddit thread, or a podcast episode, and they want to know if this is the experimental stuff with the K-holes or the medical protocol. They want to know the difference between IV ketamine at $400 per session and Spravato (esketamine), which insurance often covers. They want to know if their treatment-resistant depression qualifies. A 40-minute education call is the standard, and most clinics convert maybe 15% of cold inquiries because the call never gets booked.

SleekAI maps your protocol custom post type with route_of_administration (IV, IM, intranasal, sublingual), session_count, session_price (typically $400 to $650 for IV, $100 to $250 for IM, $590 to $885 per Spravato dose), session duration (60 to 90 minutes for IV, 120 minutes for Spravato monitoring), and contraindication taxonomy. The bot explains each protocol, asks about prior treatment-resistant depression diagnosis, current SSRIs, cardiovascular history, and substance use, then books a 30-minute consultation if appropriate.

Generic bots cannot do ketamine education. They mix up street ketamine and medical ketamine. They cannot explain why Spravato (esketamine) is FDA-approved while compounded ketamine is off-label. They miss critical contraindications like uncontrolled hypertension or active psychosis. SleekAI uses your real protocol text and contraindication list, so the conversation matches your clinic's clinical standards exactly. The consult rate goes up because patients arrive prepared instead of confused.

Ketamine therapy is one of the highest-curiosity, lowest-literacy specialties in healthcare. Patients come in with wildly varying levels of understanding. Some have read every paper on glutamate signaling and want to discuss NMDA antagonism.

Others have only seen a glossy ad and assume ketamine is recreational. Both deserve accurate information, and a chatbot is uniquely positioned to give it without burning out the clinical staff. The economics also matter.

An IV ketamine induction series at $475 per session totals nearly $3,000 in revenue per patient, and most clinics convert maybe 10 to 20% of cold website inquiries to a booked consult. Lifting that to 25% by pre-qualifying and educating doubles bookings without spending more on ads. The Spravato pathway is even more leveraged because insurance covers most of the medication cost, so the patient's out-of-pocket is often just a copay.

Patients who learn this earlier are dramatically more likely to follow through. The contraindication screening protects the clinic's time too. A patient with uncontrolled hypertension or active psychosis will be turned away after the consult, which means a wasted appointment slot and a frustrated patient.

By screening up front, the bot routes those patients toward primary care optimization or alternative treatments and keeps the clinic's consult calendar full of qualified candidates. The transcripts also surface what patients are actually confused about. Most clinics learn within two weeks that their website does not adequately explain Spravato versus IV, or the difference between induction and maintenance, or what KAP integration actually involves.

Updating the site based on real questions tightens conversion further and reduces the chatbot's own workload over time.